ClinicalTrials.gg
Active, not recruitingNCT02381353Updated Jan 12, 2026

Exparel Injection for Postoperative Orbital Pain

A Phase 4 interventional study of Bupivacaine in Pain, Postoperative, sponsored by Mayo Clinic. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Planned enrollment
142nd of 364
88 · median 70
Started
2015
with 24 others
Phase 4
133 of 364
18 open now
Primary completion
2026-12
later than 32 of 59 live
Registered
61st of 364
by date
Lead sponsor
4 of 364
Mayo Clinic

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 142nd largest by planned enrollment, is one of 25 that started in 2015, is one of 133 in phase 4, reaches primary completion later than 32 of the 59 other live ones, and was the 61st registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

After surgery to remove the eye, either by enucleation or evisceration, patients have variable levels of pain for several postoperative days. Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale. The current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. In 2011, Pacira Pharmaceuticals released a bupivacaine liposomal injectable suspension (Exparel, 1.3%) which offers sustained release of bupivacaine giving postoperative pain control for up to 72 hours. This medication has been used in numerous surgeries including inguinal hernia repair, hemorrhoidectomy, bunionectomy, breast reconstruction, and orthopedic surgery, and the literature reports improved pain control, decreased use of oral opioids, and increased patient satisfaction. There are no reports of the use of Exparel in the ophthalmic literature. The investigators propose a randomized, controlled trial to compare the postoperative pain control offered by sustained release bupivacaine to that offered by standard plain bupivacaine after enucleation or evisceration.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • Enucleation
  • Evisceration
  • Exparel
  • bupivacaine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients undergoing enucleation or evisceration of the eye whose surgery is performed by the Department of Ophthalmology at Mayo Clinic Rochester
  2. Willing and able to comprehend a numerical rating scale system and provide a score to assess pain, nausea, and satisfaction level.

Exclusion criteria

Exclusion criteria:

  1. Age less than 18 years (Exparel has not been tested in a pediatric population)
  2. Pregnant or nursing (Exparel has not been tested in this patient population)
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Plain bupivacaine

    Intraoperative injection of local anesthetic agent, standard of care

    Drug: Bupivacaine

  • Experimental
    Exparel (sustained release bupivacaine)

    Intraoperative injection of local anesthetic agent, long acting agent

    Drug: Bupivacaine

Interventions

  • Intraoperative orbital injection of local pain medication

    Also known as: Exparel

06

What researchers measure

Primary outcomes

  1. Postoperative orbital pain

    Pain on a scale of 0-10, assessed on day 3 post enucleation or evisceration

    Time frame: Days 3 postoperatively

Secondary outcomes

  1. Postoperative nausea and vomiting

    Nausea and vomiting on a scale of 0-3, assessed on day 3 post enucleation or evisceration

    Time frame: Days 3 postoperatively

  2. Quantity of oral narcotics used for postoperative pain control

    Number of oral narcotic pills taken during postoperative days 0-3

    Time frame: Days 3 postoperatively

  3. Patient satisfaction

    Overall satisfaction with postoperative recovery, assessed on a scale of 1-5

    Time frame: Day 3 postoperatively

  4. Postoperative complications

    Assessment of any postsurgical complications completed at postoperative visit

    Time frame: 6-8 weeks postoperatively

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — University of Michigan will share patient study data with Mayo site. A Data Use Agreement has been approved for this purpose.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: From July 2024 through end of reporting period.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2015
First posted
Mar 6, 2015
Start
Feb 2015
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02381353
Lead sponsor
Mayo Clinic
Responsible party
Elizabeth A. Bradley, M.D. (PI, Mayo Clinic) — Principal investigator
First posted
Mar 6, 2015
Start date
Feb 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Elizabeth Bradley, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion